We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+3.46%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.35B
AUM Growth
-$141M
Cap. Flow
+$107M
Cap. Flow %
3.2%
Top 10 Hldgs %
41.69%
Holding
77
New
11
Increased
22
Reduced
20
Closed
9

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$68M
2
APLS
Apellis Pharmaceuticals
APLS
+$67.9M
3
TGTX icon
TG Therapeutics
TGTX
+$45.8M
4
KRRO icon
Korro Bio
KRRO
+$42.6M
5
AXSM icon
Axsome Therapeutics
AXSM
+$40.6M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$108M
2
GERN icon
Geron
GERN
+$68.2M
3
APGE
Apogee Therapeutics
APGE
+$64.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.5M
5
TRML
Tourmaline Bio
TRML
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
2 Miscellaneous 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
1
Amgen
AMGN
$203B
$180M 5.36%
575,000
+25,000
+5% +$7.34M
ARGX icon
2
argenx
ARGX
$61B
$172M 5.13%
400,000
+100,000
+33% +$38.3M
AXSM icon
3
Axsome Therapeutics
AXSM
$11.1B
$149M 4.45%
1,852,784
+548,063
+42% +$40.6M
DYN icon
4
Dyne Therapeutics
DYN
$3.29B
$141M 4.21%
4,000,000
-555,383
-12% -$16.1M
SWTX
5
DELISTED
SpringWorks Therapeutics
SWTX
$139M 4.16%
3,700,000
+220,147
+6% +$9.27M
INSM icon
6
Insmed
INSM
$26.5B
$134M 4%
2,000,000
-2,783,679
-58% -$108M
GH icon
7
Guardant Health
GH
$23.6B
$130M 3.88%
4,500,000
-1,500,000
-25% -$34.9M
DVAX
8
DELISTED
Dynavax Technologies
DVAX
$122M 3.65%
10,900,000
+1,758,340
+19% +$20.5M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$31.9B
$122M 3.63%
500,000
-332,310
-40% -$52.5M
NTLA icon
10
Intellia Therapeutics
NTLA
$1.63B
$107M 3.21%
4,800,000
+589,216
+14% +$14M
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$105M 3.14%
1,537,922
+37,922
+3% +$2.63M
APLS
12
DELISTED
Apellis Pharmaceuticals
APLS
$95.9M 2.86%
2,500,000
+1,500,000
+150% +$67.9M
IONS icon
13
Ionis Pharmaceuticals
IONS
$7.75B
$95.3M 2.85%
2,000,000
+626,525
+46% +$25.7M
OCUL icon
14
Ocular Therapeutix
OCUL
$2.25B
$87M 2.6%
12,721,460
– –
FDMT icon
15
4D Molecular Therapeutics
FDMT
$759M
$85.2M 2.54%
4,061,401
+1,026,948
+34% +$25.8M
ALKS icon
16
Alkermes
ALKS
$7.73B
$84.3M 2.52%
3,500,000
– –
NRIX icon
17
Nurix Therapeutics
NRIX
$2.59B
$83.3M 2.49%
3,991,500
+993,670
+33% +$15.5M
IMVT icon
18
Immunovant
IMVT
$7.66B
$76.1M 2.27%
2,883,736
+2,390,384
+485% +$68M
BCYC
19
Bicycle Therapeutics
BCYC
$258M
$70.6M 2.11%
3,490,506
– –
PLRX icon
20
Pliant Therapeutics
PLRX
$71.2M
$64.2M 1.92%
5,972,257
+222,257
+4% +$2.87M
TVTX icon
21
Travere Therapeutics
TVTX
$5.97B
$60.6M 1.81%
7,370,000
– –
VRNA
22
DELISTED
Verona Pharma
VRNA
$57.8M 1.73%
4,000,000
+812,585
+25% +$11.9M
ABVX
23
Abivax
ABVX
$9.05B
$55.3M 1.65%
4,179,763
-117,675
-3% -$1.68M
GERN icon
24
Geron
GERN
$835M
$55.1M 1.65%
13,000,000
-17,505,929
-57% -$68.2M
AUTL
25
Autolus Therapeutics
AUTL
$514M
$53.1M 1.59%
15,272,172
– –
1
2 3 4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Deep Track Capital held 77 positions worth $3.35B, down 4% from $3.49B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deep Track Capital deployed $107M of net new capital in Q2 2024, opening 11 new positions and adding to 22 existing holdings. Its largest new stake was TG Therapeutics: 2,870,131 shares worth $51.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Insmed, an estimated $108M trimmed.

  • Deep Track Capital's largest Q2 2024 buy was TG Therapeutics: 2,870,131 shares worth $51.1M.
  • Deep Track Capital added most to Immunovant in Q2 2024, an estimated $68M increase.
  • Deep Track Capital's biggest Q2 2024 reduction was Insmed, cutting an estimated $108M.
  • Deep Track Capital fully exited Tourmaline Bio in Q2 2024, selling an estimated $36.5M.
  • Deep Track Capital's ten largest holdings make up 42% of its $3.35B portfolio in Q2 2024.
  • Deep Track Capital opened 11 new positions and closed 9 in Q2 2024.
  • Deep Track Capital's portfolio value fell 4% quarter-over-quarter to $3.35B.

Based on Deep Track Capital's 13F filing for Q2 2024, filed 14 Aug 2024.